Aganirsen

DB15369InvestigationalGene Therapies

Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).

Mechanism: Pharmacologically active on Insulin receptor substrate 1
Curator reviewed
Code names: GS-101

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Aganirsen, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.